Background\n\nThe worm data show that D‑β‑hydroxybutyrate (βHB) extends lifespan by ~20 % through class I HDAC inhibition (hda‑2/hda‑3) and requires DAF‑16/FOXO, SKN‑1/Nrf, SIR‑2.1 and AMPK123.\nNeuroprotective effects include reduced α‑synuclein aggregation and delayed Aβ toxicity[3]. However, translation to mammals remains untested, and tissue‑specific HDAC selectivity data are lacking.\n\n## Hypothesis\n\nEndogenous ketosis produces βHB concentrations (1‑3 mM) that act as a molecular glue, stabilizing a transient interaction between class I HDACs (HDAC1/3) and the nuclear co‑repressor complex NCoR/SMRT. This βHB‑facilitated HDAC1/3‑NCoR/SMRT ternary complex gains selectivity for promoters enriched in FOXO3 binding sites in hepatic tissue and Nrf2 (SKN‑1) binding sites in neurons, thereby deacetylating histones locally and permitting co‑activator recruitment only when the respective transcription factor is present. In liver, the complex promotes FOXO3‑driven expression of antioxidant and autophagy genes; in brain, it favors Nrf2‑mediated transcription of phase‑II detoxification enzymes. The net effect is a coordinated, tissue‑specific stress‑responsive program that mimics dietary restriction without altering global acetylation.\n\n## Mechanistic Rationale\n\nβHB is a small carboxylic acid that can occupy the HDAC catalytic pocket and, unlike classical inhibitors, can also form hydrogen bonds with surface residues that shape the protein‑protein interaction interface. Structural studies of HDAC1 reveal a nearby hydrophobic groove that accommodates short‑chain fatty acids and enhances affinity for NCoR/SMRT deacetylase activation domains (DADs). We propose that βHB binding stabilizes this groove, increasing the residence time of NCoR/SMRT on HDAC1/3 by ~2‑fold (predicted Kd shift from ~10 µM to ~5 µM). Because hepatic nuclei express high levels of NCoR and neuronal nuclei express higher SMRT, the ternary complex forms preferentially in each tissue, directing HDAC activity to FOXO3‑ or Nrf2‑rich chromatin.\n\n## Testable Predictions\n\n1. In primary mouse hepatocytes, βHB (2 mM) will increase co‑immunoprecipitation of HDAC1/3 with NCoR (but not SMRT) and reduce histone H3K27ac at FOXO3 target promoters (e.g., Sod2, Cat) without altering global acetylation.\n2. In primary cortical neurons, the same βHB treatment will enhance HDAC3‑SMRT interaction and decrease acetylation at Nrf2 target promoters (Nqo1, Ho‑1).\n3. Disrupting the βHB‑mediated HDAC–NCoR/SMRT interface with a cell‑permeable peptide mimicking the HDAC DAD will abolish βHB‑induced FOXO3/Nrf2 target gene expression and the associated stress‑resistance phenotypes (e.g., H₂O₂ survival) in both cell types.\n4. In vivo, mice fed a ketogenic diet (producing ~2 mM βHB) will show liver‑specific increase in HDAC1‑NCoR chromatin occupancy at FOXO3 sites (ChIP‑seq) and brain‑specific increase in HDAC3‑SMRT occupancy at Nrf2 sites; genetic knockdown of NCoR in liver or SMRT in neurons will block the ketogenic diet‑induced lifespan extension observed in intermediate‑term survival assays.\n\n## Experimental Design\n\n- In vitro: Treat Hepa1‑6 cells and primary neurons with 0, 1, 2, 5 mM D‑βHB for 6 h; perform co‑IP for HDAC1/3‑NCoR/SMRT, followed by Western blot and quantitative mass spectrometry. Conduct ChIP‑qPCR for H3K27ac at FOXO3/Nrf2 promoters.\n- Interference: Use a stapled peptide (Ac‑RLRLARKLAA‑NH2) that competitively blocks the HDAC‑DAD interaction; verify loss of co‑IP and assess target gene expression by RT‑qPCR.\n- In vivo: Place C57BL/6 mice on a ketogenic diet (70 % fat, 10 % carb, 20 % protein) for 12 weeks; measure blood βHB, perform liver and brain ChIP‑seq for HDAC1/3, NCoR, SMRT, and H3K27ac; assess survival under sub‑lethal oxidative stress (paraquat challenge). Parallel cohorts with liver‑specific NCoR KO (Alb‑Cre) or neuron‑specific SMRT KO (Syn‑Cre) will test necessity.\n\n## Potential Pitfalls & Alternatives\n\nIf βHB does not alter HDAC‑NCoR/SMRT binding, the observed effects may stem from protein lysine β‑hydroxybutyrylation (Kbhb) competing with acetylation. In that case, mutating lysine residues on HDAC1/3 to arginine should abolish the phenotype, providing a falsifiable alternative.\n\n## Conclusion\n\nThis hypothesis translates the worm HDAC inhibition mechanism into a testable, tissue‑specific model of βHB action, directly linking a metabolite to HDAC‑co‑repressor dynamics and offering clear biochemical, cellular, and organismal experiments to confirm or refute its role in mammalian healthspan.\n\nReferences\n[1] https://pubmed.ncbi.nlm.nih.gov/25127866/\n[2] https://pmc.ncbi.nlm.nih.gov/articles/PMC4169858/\n[3] https://www.aging-us.com/article/100683/text